GDS Holdings (GDS) : 8-year performance

GDS Holdings Limited primarily develops and operates data centers in the People's Republic of China. 

• Sector: Technology
• Industry: Information Technology Services
• Full Time Employees: 2,345
• Founded in 2001 
• Headquartered in Shanghai, China.
• https://www.gds-services.com

Here are the key services and operations of GDS Holdings:

• Colocation Services: They provide critical facilities space, customer-available power, racks, and cooling for businesses to house their servers and IT equipment.
• Managed Hosting Services: This includes services like business continuity, disaster recovery, network management, data storage, system security, operating system, database, and server middleware services.
• Managed Cloud Services: GDS offers services that help manage cloud environments, allowing direct private connections to major public cloud platforms.
• Consulting Services: They offer advice and expertise in IT infrastructure management.

Their data centers are described as carrier and cloud-neutral, meaning customers can connect to major telecommunications networks and access various public cloud services hosted within their facilities. GDS Holdings serves a diverse clientele including cloud service providers, large Internet companies, financial institutions, telecommunications and IT service providers, and both domestic and multinational corporations.

 

Pulse Biosciences (PLSE) : 8-year performance

Pulse Biosciences CEO Burke T. Barrett to resign, effective today; also to resign from Board

• The Company's Chief Commercial Officer, Kevin P. Danahy, and its Chief Technology Officer, Darrin R. Uecker, will serve as the Company's principal executive and principal financial officers until such time as the Company has identified a chief executive officer to replace Mr. Barrett.
• Messrs. Danahy and Uecker have both served as the Company's Chief Executive Officer at different times before Mr. Barrett.

3 days later

Evoke Pharma (EVOK) : New FDA Market Exclusivity For Gimoti Nasal Spray

  

 

The FDA has granted new drug product exclusivity to Evoke Pharma Inc's (NASDAQ: EVOK) Gimoti (metoclopramide) nasal spray to relieve symptoms associated with acute and recurrent diabetic gastroparesis in adults.

Evoke now has exclusive marketing rights over three (3) years from the original date of approval under the Hatch-Waxman Act to protect the product from generic drug competition.

In addition to the market exclusivity, Evoke maintains a robust patent estate, with currently two Orange book-listed patents that expire in 2029 and 2030.

The Company has also been granted gender-specific patents in the EU, Japan, and Mexico until 2032.

Furthermore, if approved, Evoke has other pending patent applications with individual expiration dates of 2032, 2037, and 2038.

Ares Management (ARES) : 8-year performance

• May 2, 2014: Ares Management shares fell to close at $18.17, a decline of 4.4 percent from the IPO price. Ares cut the size of the offering to 11.4 million units from 18.2 million units, and the IPO priced below the estimated range of $21 to $23. The deal generated proceeds of $217 million and gave Ares a market cap of about $4 billion, or about 4.7x its 2013 net income of $850 million.
• https://www.aresmgmt.com/

 

American Homes 4 Rent (AMH) : 8-year performance

 

CareDx Inc. (CDNA) reported earnings on Thur 28 Oct 21 (a/h)

•  For Q3, co posted upside results for EPS and for revs, which rose +42% yr/yr to $75.6 mln. Testing services volume grew +86% yr/yr. Raised its guidance for FY21 revs to $290-293 mln, in-line with estimates. Falls to 52-week lows. 

** charts after earnings **

 

CareDx beats by $0.05, beats on revs; raises FY21 revs in-line

• Reports Q3 (Sep) earnings of $0.07 per share, excluding non-recurring items, $0.05 better than the S&P Capital IQ Consensus of $0.02; revenues rose 41.6% year/year to $75.6 mln vs the $74.11 mln S&P Capital IQ Consensus.
• Co issues raised guidance for FY21, sees FY21 revs of $290-293 mln from $280-290 mln vs. $290.48 mln S&P Capital IQ Consensus.

GW Pharma (GWPH) to be acquired by Jazz Pharmaceuticals (JAZZ) for about $7.2 billion

• GW Pharmaceuticals (NASDAQ:GWPH) (UK-based) was acquired by Ireland-based Jazz Pharmaceuticals (NASDAQ:JAZZ) for $7.6 billion. (Completed in May 2021) 

   

 

 

Workday (WDAY) reported earnings on Thur 19 Nov 2020 (a/h)

  ** charts after earnings **

 

Workday beats by $0.19, beats on revs, raises FY21 subscription revenue guidance

Reports Q3 (Oct) earnings of $0.86 per share, $0.19 better than the S&P Capital IQ Consensus of $0.67; revenues rose 18.3% year/year to $1.11 bln vs the $1.09 bln S&P Capital IQ Consensus.

Reports subscription revenue backlog of $8.87 bln, up 23.4% yr/yr.

Outlook: "Based on our strong third quarter, we are raising our fiscal 2021 subscription revenue guidance to a range of $3.773-$3.775 billion. As we enter Q4, we are increasing our pace of investments to capitalize on the long-term opportunity that we see ahead."

Co commented during its call that it expects remaining headwinds due to COVID to be more fully evident in next year's subscription revs, weighing on co's growth in the near term.

GRPN : downgraded to sell from neutral at Goldman

Ticker: GRPN

 

Carbonite (CARB) to be acquired by OpenText (OTEX) for $23.00/share

Carbonite has agreed to a $1.42 billion purchase by OpenText, an enterprise information management giant, ending weeks of speculation about the anticipated buyout.

 

 

The deal marks a 78% premium on Carbonite's share price on September 5, when it was first rumored the company was preparing to buy the backup and data recovery company. Carbonite said the board "strongly believes" the deal will return "substantial" cash value to shareholders, said Steve Munford, chairman of Carbonite's board.

It ends a busy couple of years for Carbonite as the company has moved away from a traditional data backup business to a more proactive, defensive security company.

In February, Carbonite bought endpoint security company Webroot for $618.5 million in an all-cash deal, as the company pushed to protect against emerging threats like ransomware. Only a year earlier, Carbonite bought Mozy for $145 million, a cloud backup service.

Carbonite said at the time of its acquisition by OpenText, the backup company had losses of $14 million on revenues of $125.6 billion, an increase by 62% year-over-year.

******

 

******

Carbonite beats by $0.12, reports revs in-line

Reports Q3 (Sep) earnings of $0.61 per share, $0.12 better than the S&P Capital IQ Consensus of $0.49; revenues rose 61.9% year/year to $125.8 mln vs the $125.76 mln S&P Capital IQ Consensus.

Adjusted EBITDA of $40.2 mln, or 30% of non-GAAP revenue, compared to $23.0 mln, or 29% of non-GAAP revenue in 2018.